Hydrogen sulfide to modulate Glycated hemoglobin and gut microbiome in type 2 diabetes mellitus
Metabolism Open, Volume 28, 2025
23
October, 2025
1
January, 2021
Diabetes on sepsis outcomes in non-ICU patients: A cohort study and review of the literature
Karolina Akinosoglou, Georgia Kapsokosta, Maria Mouktaroudi, Nikoletta Rovina, Vassileios Kaldis, Aggelos Stefos, Marina Kontogiorgi, Evangelos J. Giamarellos-Bourboulis, Charalambos Gogos, Hellenic Sepsis Study Group Journal of Diabetes and Its Complications 2021 Jan;35(1):107765 DOI: 10.1016/j.jdiacomp.2020.107765View article 🡇 Funding The works were supported by the BMBF within the framework of the “MetaZIK”/ZIK Septomics Jena (03Z2J521),
1
November, 2019
INCREDIBLE-ME
Ongoing study Official Study Title Gut-derived INCREtin hormones in the pathophysiology of Type 1 DiaBetes MeLlitus; Effect of Metformin treatment (the INCREDIBLE-ME trial) Brief Description INCREDIBLE-ME is a randomized clinical trial aiming to study the effect of adjunct metformin treatment to insulin monotherapy in patients with type 1 diabetes, targeting the intestinal incretin secretion.
1
September, 2019
Late Peaks of HMGB1 and Sepsis Outcome: Evidence For Synergy With Chronic Inflammatory Disorders
Eleni Karakike, Maria-Evangelia Adami, Malvina Lada, Theologia Gkavogianni, Ioannis M Koutelidakis, Michael Bauer, Evangelos J. Giamarellos-Bourboulis, Iraklis Tsangaris Shock 2019 Sep;52(3):334-339 DOI 10.1097/SHK.0000000000001265 View article 🡇 Funding The study was funded by unrestricted educational grants provided by the Hellenic Institute for the Study of Sepsis, by the Horizon 2020 Marie